Search results
Results from the WOW.Com Content Network
Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries. It acts as a platelet aggregation inhibitor by antagonising the P2Y 12 receptor. [7]
These side effects are serious and some of them are permanent, and many remain a crucial concern for companies and healthcare professionals and substantial efforts are being encouraged to reduce the potential risks for future antipsychotics through more clinical trials and drug development.
Common side effects include nausea, dry mouth, diarrhea, constipation, vomiting (3-6% of people), and sexual dysfunction. [15] [11] Serious side effects may include suicide in those under the age of 25, serotonin syndrome, bleeding, mania, and SIADH. [15] A withdrawal syndrome may occur if the medication is abruptly stopped or the dose is ...
AstraZeneca Plc (AZN) announced on Thursday that the Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted a priority review for its heart ...
More than a year after AstraZeneca (AZN) filed for approval of its potential blockbuster heart drug Brilinta, the Food and Drug Administration appears ready to make its decision on Thursday. The ...
AstraZeneca (AZN) announced that it failed to win the approval of the U.S. Food and Drug Administration for its heart drug Brilinta, a blood-thinner that the company -- facing a severe patent ...
UFH is classified as Pregnancy Category C, which means animal studies have shown potential for adverse effects to the fetus; however, there needs to be more studies done to confirm the presence of a risk to the fetus. UFH can be used in pregnant women as long as the benefits outweigh the risk. [37]
Bentracimab is a monoclonal antibody medication which has been shown in phase one and two clinical trials to function as a reversal agent for the anti–blood clotting drug ticagrelor (which acts as a P2Y 12 inhibitor and is sold under the brand name Brilinta among others). [2]